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once candidates were identified, all recruitment efforts could be directly targeted 
to specific patients as opposed to advertising to a large, undefined population or 
relying on physician referral. This resulted in improved patient response rates, 
which could conceivably be improved further with the creation of more targeted 
recruitment materials developed by patient demographic profiles generated from 
EMR data.
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Objectives: Real world evidence (RWE)-based tools are important to fill data 
gaps and capture real world cost and treatment patterns in economic modeling. 
The objective of this study was to assess the capabilities of US-based longitu-
dinal, retrospective data assets to inform health economic models in diabetes 
and oncology. MethOds: To illustrate the availability of RWE data for modeling, 
several IMS data assets were compared in a landscape assessment, including 
Pharmetrics Plus (PMTX+), Oncology Electronic Medical Record (EMR), Ambulatory 
EMR, Charge Data Master (CDM), Pharmacy (LRx), Office Based Medical Claims 
Data (Dx), and Laboratory Data (Labs). Diabetes and oncology were chosen to 
illustrate the range of needed inputs across commonly modeled diseases. Data 
availability was assessed in a matrix framework across core categories of model 
inputs including: treatment patterns, epidemiology, adverse events (AEs), patient 
health metrics (i.e., BMI), costs, resource use, and disease status. Results: For 
oncology, inputs for treatment patterns (PMTX+, Oncology EMR), epidemiology 
(PMTX+, Oncology EMR, CDM), AEs (PMTX+, Oncology EMR, CDM), and resource 
use (PMTX+, Oncology EMR) are available in several data assets but information 
on patient health metrics and disease status may require leveraging the Oncology 
EMR database to capture sufficient detail. For diabetes, availability of data for 
populating models is more robust increasing information on treatment patterns 
(PMTX+, LRx linked to Dx), epidemiology (PMTX+, Ambulatory EMR, CDM), resource 
use (PMTX+, Labs, Dx), AEs (PMTX+, Ambulatory EMR, CDM, Dx), and patient health 
metrics (Ambulatory EMR, CDM). While several databases report cost outcomes, 
the most relevant costs for modeling are found in PMTX+. cOnclusiOns: Core 
concepts for economic modeling can be populated with RWE assets in the US 
though no single database is likely to cover all inputs. The choice of data should 
be informed by the research question, patient counts and the ability to link 
databases.
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Objectives: Longitudinal Patients Database (LPD) is a primary care database of 
anonymized electronic medical records (EMR) from about 4 % of the French popu-
lation. Diagnosis and prescription data are routinely collected from proprietary 
practice management software used by physicians (primary care and specialists) 
to maintain EMR of their patients. Although LPD has been extensively validated 
by numerous publications and its use by French National Health Authorities, this 
is the first time that its representativeness and validity is systematically exam-
ined. MethOds: The distribution of several variables were analyzed and compared 
to available literature. Part of these variables refers to physician’s practices partici-
pating to the database while others refer to patients in these practices. Data about 
prevalence, treatments, and patients profile were retrieved from published French 
Health Authorities studies based on LPD data and compared to other published 
sources. Results: The sampling methods for the physician’s selection practices 
were shown to provide a good representativeness of the physician panel. Analyze 
of the patients population showed that LPD included all the subsets of the French 
general population, although pediatrics were underrepresented. Prevalences of 
several illnesses (diabetes, asthma, atrial fibrillation, aortic aneurism), treatments 
(dyslipidemia, diabetes), patients’ profiles (dyslipidemia, atrial fibrillation, venous 
disease) were in agreement to those encountered in literature. However, smok-
ing status, hospitalizations, referral to specialists were only partially reported and 
no information was available about sociodemographic status or death of patients. 
The availability of missing information through the use of questionnaires/pop up 
screens for physicians and patients, and the linkage of the EMR database to a claims 
database (HEAD) is also documented. cOnclusiOns: We found no indications of 
lack of representativeness or validity of the LPD. While presenting some flaws asso-
ciated with its naturalistic nature, LPD is a good support for pharmacoepidemiologi-
cal and pharmacoeconomics studies.
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Objectives: To investigate the risk of Chronic Humoral Rejection (CHR) due to Lack 
of Adherence to Immunosuppressive Treatment (LAIT) in Kidney Transplant (KT) 
patients using Computer Assisted Qualitative Data Analysis (CAQDAS). MethOds: 
A systematic literature review was conducted using Medline, Psycinfo and BVS to 
identify studies published between 2009 and 2013 on CHR due to LAIT in KT patients. 
Based on this review a questionnaire was developed focussing on the information 
gaps identified. Six physicians from major Spanish Transplant centres then com-
ages ranged from 0.83% to 2% respectively. All-cause healthcare Per Patient Per Year 
costs were approximately $13,200 in each database. cOnclusiOns: Creation of a 
database using a CDM approach allows for simultaneous examination of standard-
ized claims across databases, thus broadening the efficiency and generalizability of 
retrospective claims analyses. The diverseness of comorbidities among HCV patients 
combined with the evolving treatment landscape makes it an ideal candidate for 
this type of research.
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Objectives: Lack of a coordinated primary care system is forcing individuals to 
seek emergency departments (EDs) as gateway into the health system. As volumes 
increase and cases become more complex, combined with inadequate downstream 
capacity lead to boarding, bottlenecks and wait times. The goal was to review ben-
efits of Radio Frequency identification (RFID) demonstrated in the literature in the 
ED. MethOds: Article searches were conducted and they were categorized based 
on benefits in three areas: patients, staff, assets. Results: Evidence of use of RFID 
in ED went as far back as 2006 with both domestic and international applications 
mostly using active technology. Majority of the articles demonstrated reducing 
wait times in the ED. One of the articles in turn demonstrated impact on patient 
satisfaction. Reduction in wait times were demonstrated when admitting patients 
into ICU from the emergency setting. In case of staff, use of RFID demonstrated 
increased satisfaction in a pediatric emergency setting. Evidence also exists in bet-
ter tracking of assets and equipment in the ED. Very little evidence of use of RFID 
in simulation and analytical models exist. Most of the studies were retrospective 
in nature. Wait times and asset tracking are tangible benefits with direct impact on 
return-on-investment. cOnclusiOns: RFID has been used is various settings in 
healthcare and quality benefits have been demonstrated. Lesser evidence of RFID 
use in the ED exists. RFID benefits have primarily been demonstrated with regard 
to wait times and asset tracking and management. Patient and staff satisfaction 
are more intangible benefits. As EDs start to reap benefits with wait times, use in 
simulation and advanced analytical models could potentially inform workload, 
team configuration and team dynamics studies. As healthcare moves into the 
era of big data, live streaming RFID data can be tapped for real-time decision 
making.
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Objectives: To evaluate the most common reasons provided by peer-reviewed 
journals to reject manuscripts describing data derived from real-world or health-
economic (RW/HE) studies. MethOds: Our company project administration 
records from the last 10 years were reviewed for manuscripts describing HE stud-
ies, RW/observational studies (including retrospective database analyses), and 
patient or disease registries. Reasons for rejection were collected and stratified 
into “categories”. If more than one reason was provided by the journal, then all 
reasons were counted. Our analysis was based on industry-sponsored manuscripts 
for which a complete submission history was available. Results: Rejection let-
ters were collected for 78 manuscripts. Of these, 12 did not specify a reason for 
rejection. The remaining records revealed a total of 100 rejection counts. The most 
common reasons were ‘priority rating not high enough’ (33%), ‘concerns about the 
methodology’ (18%), and ‘information not sufficiently novel’ (15%). Other reasons 
for rejection included ‘topic not appropriate for the journal’ (7%), ‘manuscript is 
biased/conclusions are too strong’ (5%), ‘industry involvement not sufficiently 
disclosed’ (2%), and referral to a sister journal instead (2%). cOnclusiOns: 
These common reasons for rejection could provide authors with some guidance 
on which factors are particularly important to focus on during the development of 
a RW/HE manuscript to help improve the chances of acceptance by peer-reviewed 
journals.
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Objectives: Much of the increase in health-care expenses in the U.S. can be 
traced to the development of new drug therapies; with the average discovery 
and development process costing over $1.4 billion per drug. This motivates the 
need to reduce drug costs through more efficient drug development and testing, 
specifically, by streamlining clinical trials. The current study aims to implement 
and evaluate a process, using a data driven approach, to recruit patients for a 
clinical trial for an asthma treatment. Our hypothesis is that recruitment could 
be improved and accelerated with the support of an EMR network to identify 
patients. MethOds: All trial protocol eligibility criteria were reviewed in the con-
text of EMR data availability, as well as protocol-specific procedures. We then que-
ried our EMR network to identify sites with high patient concentrations. Four sites 
were recommended to the team by partners in this network and selected, with 
one site opting not to participate in the study after being selected. Results: EMR 
queries identified over 300 potentially eligible patients at three different sites. Of 
identified patients who were contacted, and for whom information was available, 
84% responded to outreach efforts, which represents a very substantial increase 
over the 10% that is typical in the industry. Among respondents, enrollment rates 
ranged from 14% to 40%. cOnclusiOns: For all participating sites, querying EHR 
data proved to be an effective means of identifying eligible patients. Furthermore, 
